Legend Biotech Reports Strong Q1 2026 Performance with $597M in CARVYKTI Sales, Up 62% Year-over-Year

▎Armstrong

On April 14, 2026, Johnson & Johnson released its Q1 financial report, with revenue of $24.1 billion, a year-on-year increase of 9.9%. Among this, the innovative drug business revenue reached $15.4 billion, marking an 11.2% year-on-year growth.

Innovative drug business, oncology drug revenue reached $69.73 billion, with Carvykti as one of the core growth drivers.

Johnson & Johnson's CD38 antibody Darzalex achieved sales of $3.964 billion in the first quarter, representing a year-over-year increase of 22.5%. Legend Biotech's BCMA CAR-T therapy Carvykti reported first-quarter sales of $597 million, marking a 62.1% year-over-year growth. The EGFR/cMET bispecific antibody Rybrevant generated sales of $257 million in the first quarter, reflecting an 82.7% year-over-year increase.

Summary

Global Cell Therapy Market Size to Reach $6.122 Billion in 2025, Growing 32.9% Year-over-Year, Still in a Stage of Rapid Growth. Legend Biotech/Johnson & Johnson's Carvykti Tops Best-Selling CAR-T Therapy for the First Time; Carvykti’s Sales Projected to Exceed $2.5 Billion by 2026, Becoming the First Blockbuster Drug in the CAR-T Field.Legend Biotech is expected to achieve operational profitability at the company level by 2026. Carvykti is another classic case of commercial success in the internationalization process following zanubrutinib.